PepGNP-SARSCoV2 (Emergex)

N/A

Report date: 2026/02/07 20:00:33

Base Information

Drug NamePepGNP-SARSCoV2 (Emergex)
Drug Alias NameT-Cell Priming COVID-19 vaccinenaNo-COVIDPepGNP-COVID19CoronaTcP
ClassificationVaccines > Development/production technology > Synthetic peptide vaccineVaccines > Application > Prophylactic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Coronavirus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPhilippinesSwitzerland
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesGylden Pharma Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)Gylden Pharma Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Coronavirus Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A